This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignee: Toray Industries, Inc.. Active years: 2010-2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Aichi, JP (2010)
- Mishima, JP (2012)
Company Filing History:
Years Active: 2010-2012
Title: Masahiro Akimoto: Innovator in Pharmaceutical Crystallization
Introduction
Masahiro Akimoto is a notable inventor based in Mishima, Japan. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of crystalline micropowder particles and morphinan derivatives. With a total of 2 patents, his work focuses on enhancing the bioavailability and stability of pharmaceutical compounds.
Latest Patents
Akimoto's latest patents include innovative methods for producing crystalline particles of N-(17-cyclopropylmethyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6β-yl)-phthalimide. These crystalline particles exhibit a specific particle diameter distribution, which enhances the bioavailability of the active substance while ensuring storage stability. His second patent involves the production of high-purity crystals of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride, providing consistent quality and purity.
Career Highlights
Masahiro Akimoto is currently employed at Toray Industries, Inc., where he continues to innovate in the field of pharmaceuticals. His work has been instrumental in advancing the understanding of crystalline forms and their applications in drug formulation.
Collaborations
Akimoto collaborates with esteemed colleagues such as Toshikazu Komagata and Takahiro Takeda, contributing to a dynamic research environment that fosters innovation and development in pharmaceutical sciences.
Conclusion
Masahiro Akimoto's contributions to the field of pharmaceutical crystallization highlight his role as a key innovator. His patents reflect a commitment to improving drug formulations and enhancing therapeutic efficacy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
